Covered recipient · General Payments record
PURVI KOTHARI MEHRA
Allopathic & Osteopathic Physicians Internal Medicine Allergy & Immunology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$2,287.71
32 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Travel and Lodging | $1,661.01 | 8 |
| Food and Beverage | $576.70 | 23 |
| Honoraria | $50.00 | 1 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Merck Sharp & Dohme Corporation | $1,614.18 | 12 |
| Eli Lilly and Company | $464.42 | 17 |
| Novo Nordisk AS | $136.66 | 1 |
| Flexion Therapeutics, Inc. | $50.00 | 1 |
| GlaxoSmithKline, LLC. | $22.45 | 1 |
Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
PURVI KOTHARI MEHRA
NPI 1336280031 · CMS profile ID 15061
Allopathic & Osteopathic Physicians / Internal Medicine / Allergy & Immunology
SAN DIEGO, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1336280031?year=2019&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- PURVI KOTHARI MEHRA, NPI 1336280031, CMS profile ID 15061. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1336280031?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). PURVI KOTHARI MEHRA, NPI 1336280031, CMS profile ID 15061. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1336280031?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- PURVI KOTHARI MEHRA, NPI 1336280031, CMS profile ID 15061, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1336280031?year=2019&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
32 matching records · $2,287.71 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–32 of 32.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | $22.45 | 07/03/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670915843 | CMS |
| Eli Lilly and Company | $8.35 | 06/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709012135 | CMS |
| Eli Lilly and Company | $4.64 | 06/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709013675 | CMS |
| Eli Lilly and Company | $18.56 | 06/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709014159 | CMS |
| Eli Lilly and Company | $3.34 | 06/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709014515 | CMS |
| Eli Lilly and Company | $4.64 | 06/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709014857 | CMS |
| Eli Lilly and Company | $25.99 | 06/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709015171 | CMS |
| Eli Lilly and Company | $44.55 | 06/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709015173 | CMS |
| Eli Lilly and Company | $18.56 | 06/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709015175 | CMS |
| Eli Lilly and Company | $33.41 | 06/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709015337 | CMS |
| Eli Lilly and Company | $136.98 | 06/20/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709015339 | CMS |
| Eli Lilly and Company | $1.86 | 06/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709016879 | CMS |
| Eli Lilly and Company | $4.46 | 06/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709016881 | CMS |
| Eli Lilly and Company | $11.14 | 06/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709016883 | CMS |
| Eli Lilly and Company | $1.86 | 06/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709016885 | CMS |
| Eli Lilly and Company | $2.60 | 06/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709017571 | CMS |
| Eli Lilly and Company | $6.50 | 06/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709017573 | CMS |
| Eli Lilly and Company | $136.98 | 06/20/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709017575 | CMS |
| Novo Nordisk AS | $136.66 | 06/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703544125 | CMS |
| Merck Sharp & Dohme Corporation | $13.91 | 05/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695804301 | CMS |
| Merck Sharp & Dohme Corporation | $30.82 | 05/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695804747 | CMS |
| Merck Sharp & Dohme Corporation | $78.41 | 05/23/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695805031 | CMS |
| Merck Sharp & Dohme Corporation | $103.13 | 05/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695804299 | CMS |
| Merck Sharp & Dohme Corporation | $24.99 | 05/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695804585 | CMS |
| Merck Sharp & Dohme Corporation | $247.06 | 05/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695804745 | CMS |
| Merck Sharp & Dohme Corporation | $50.00 | 05/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695804749 | CMS |
| Merck Sharp & Dohme Corporation | $81.19 | 05/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695805033 | CMS |
| Merck Sharp & Dohme Corporation | $209.00 | 05/21/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695804583 | CMS |
| Merck Sharp & Dohme Corporation | $247.06 | 05/21/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695804743 | CMS |
| Merck Sharp & Dohme Corporation | $502.39 | 05/21/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695804751 | CMS |
| Merck Sharp & Dohme Corporation | $26.22 | 05/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695806407 | CMS |
| Flexion Therapeutics, Inc. | $50.00 | 01/08/2019 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705866853 | CMS |
By program year
All program years on this page · sorted by year
| Program year | Amount | Records |
|---|---|---|
| PY2019 | $2,287.71 | 32 |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019
- Generated from
- OP_DTL_GNRL_PGYR2019_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2022 | Recipient | $375.00 | 2 |
| PY2022 | Principal investigator | $30,891.10 | 5 |
| PY2021 | Principal investigator | $3,333,813.44 | 59 |
| PY2020 | Recipient | $3,034.66 | 5 |
| PY2020 | Principal investigator | $1,118,926.99 | 96 |
| PY2019 | Recipient | $6,389.04 | 5 |
| PY2019 | Principal investigator | $1,783,635.66 | 134 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
139 records in PY2019
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Novo Nordisk AS | $1,978.59 | 12/19/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | NN9535-4506 | No dispute reported | 06/30/2026 | 692447033 |
| Principal investigator 1 | Novo Nordisk AS | $1,797.00 | 12/19/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | NN9535-4506 | No dispute reported | 06/30/2026 | 692447035 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $13,043.97 | 12/18/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 639741461 |
| Principal investigator 1 | Novo Nordisk AS | $3,601.69 | 12/05/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | NN9535-4506 | No dispute reported | 06/30/2026 | 692447031 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $13,643.08 | 12/05/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 639741459 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $4,139.10 | 12/05/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia | No dispute reported | 06/30/2026 | 685012477 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $8,473.00 | 12/03/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When administered Concomitantly with Influenza Vaccine in Healthy Adults 50 Years of Age or Older PNEU -FLU | No dispute reported | 06/30/2026 | 691490645 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $1,000.00 | 12/03/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When administered Concomitantly with Influenza Vaccine in Healthy Adults 50 Years of Age or Older PNEU -FLU | No dispute reported | 06/30/2026 | 691504027 |
| Principal investigator 1 | Novo Nordisk AS | $30.00 | 12/03/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | NN9535-4506 | No dispute reported | 06/30/2026 | 706668185 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 12/03/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | NN9535-4506 | No dispute reported | 06/30/2026 | 706668187 |
| Principal investigator 1 | Novo Nordisk AS | $9.99 | 12/03/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | NN9535-4506 | No dispute reported | 06/30/2026 | 706668189 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,661.20 | 11/28/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 639741455 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $13,053.06 | 11/28/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 639741457 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $11,700.00 | 11/26/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE | No dispute reported | 06/30/2026 | 691446985 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $1,275.00 | 11/22/2019 | Non-covered Recipient Entity Artemis Institute For Clinical Research | Bay1002670 Fibroids Efficacy US / EU | No dispute reported | 06/30/2026 | 629169107 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $500.00 | 11/22/2019 | Non-covered Recipient Entity Artemis Institute For Clinical Research | Bay1002670 Fibroids Efficacy US / EU | No dispute reported | 06/30/2026 | 629169365 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $1,350.00 | 11/22/2019 | Non-covered Recipient Entity Artemis Institute For Clinical Research | Bay1002670 Fibroids Efficacy US / EU | No dispute reported | 06/30/2026 | 629169621 |
| Principal investigator 1 | Novo Nordisk AS | $22.50 | 11/22/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | NN9535-4506 | No dispute reported | 06/30/2026 | 706668183 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $17,038.01 | 11/13/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 639741453 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,000.00 | 11/13/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia | No dispute reported | 06/30/2026 | 685012435 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,500.00 | 11/13/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia | No dispute reported | 06/30/2026 | 685012441 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $9,233.10 | 11/06/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia | No dispute reported | 06/30/2026 | 685012451 |
| Principal investigator 1 | Novo Nordisk AS | $4,346.73 | 10/29/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | NN9535-4506 | No dispute reported | 06/30/2026 | 692447021 |
| Principal investigator 1 | Novo Nordisk AS | $9.99 | 10/24/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | NN9535-4506 | No dispute reported | 06/30/2026 | 706668179 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 10/24/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | NN9535-4506 | No dispute reported | 06/30/2026 | 706668181 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $11,714.25 | 10/23/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 639741449 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,711.12 | 10/23/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 639741451 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $2,793.72 | 10/22/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE | No dispute reported | 06/30/2026 | 691336149 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $5,593.43 | 10/22/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE | No dispute reported | 06/30/2026 | 691337871 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $962.85 | 10/22/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE | No dispute reported | 06/30/2026 | 691372391 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $25,260.00 | 10/22/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE | No dispute reported | 06/30/2026 | 691372823 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 10/16/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | NN9535-4506 | No dispute reported | 06/30/2026 | 706668167 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 10/16/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | NN9535-4506 | No dispute reported | 06/30/2026 | 706668169 |
| Principal investigator 1 | Novo Nordisk AS | $60.00 | 10/16/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | NN9535-4506 | No dispute reported | 06/30/2026 | 706668171 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 10/16/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | NN9535-4506 | No dispute reported | 06/30/2026 | 706668173 |
| Principal investigator 1 | Novo Nordisk AS | $9.80 | 10/16/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | NN9535-4506 | No dispute reported | 06/30/2026 | 706668175 |
| Principal investigator 1 | Novo Nordisk AS | $144.00 | 10/16/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | NN9535-4506 | No dispute reported | 06/30/2026 | 706668177 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,000.00 | 10/09/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A Phase 1, Multicenter, Randomized, Open-Label, Parallel-Group, Multi-Dose Study in Patients With Moderate-to-Severe Pain Due to Osteoarthritis of the Knee or Hip to Assess the Patients' Ability to Self-Administer Fasinumab Using an Auto-Injector and to Characterize the Pharmacokinetics of Fasinumab Using Two Different Presentations | No dispute reported | 06/30/2026 | 639741445 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,538.51 | 10/09/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 639741447 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,996.00 | 10/09/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia | No dispute reported | 06/30/2026 | 685012445 |
| Principal investigator 1 | PFIZER INC. | $242,196.87 | 10/04/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE | No dispute reported | 06/30/2026 | 671658835 |
| Principal investigator 1 | Novo Nordisk AS | $23.06 | 09/27/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | NN9535-4506 | No dispute reported | 06/30/2026 | 706668217 |
| Principal investigator 1 | Novo Nordisk AS | $9.99 | 09/27/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | NN9535-4506 | No dispute reported | 06/30/2026 | 706668219 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $43,042.50 | 09/26/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE | No dispute reported | 06/30/2026 | 691346827 |
| Principal investigator 1 | Novo Nordisk AS | $2,364.76 | 09/26/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | NN9535-4506 | No dispute reported | 06/30/2026 | 692447029 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $47,520.54 | 09/25/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 639741443 |
| Principal investigator 1 | Eli Lilly and Company | $110,749.00 | 09/23/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL COMPARING EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS SEMAGLUTIDE ONCE WEEKLY AS ADD-ON THERAPY TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 654287505 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $150.00 | 09/19/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE | No dispute reported | 06/30/2026 | 691346221 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $3,870.00 | 09/19/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE | No dispute reported | 06/30/2026 | 691346819 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9,856.57 | 09/11/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 639741441 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $279.00 | 09/09/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE | No dispute reported | 06/30/2026 | 691518351 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $176.10 | 09/06/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE | No dispute reported | 06/30/2026 | 691355845 |
| Principal investigator 1 | Novo Nordisk AS | $500.00 | 09/05/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | NN9535-4506 | No dispute reported | 06/30/2026 | 692447023 |
| Principal investigator 1 | Novo Nordisk AS | $3,000.00 | 09/05/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | NN9535-4506 | No dispute reported | 06/30/2026 | 692447025 |
| Principal investigator 1 | Novo Nordisk AS | $1,000.00 | 09/05/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | NN9535-4506 | No dispute reported | 06/30/2026 | 692447027 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $372.00 | 09/03/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE | No dispute reported | 06/30/2026 | 691515431 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $23,916.78 | 08/28/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 639741437 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $12,250.61 | 08/28/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 639741439 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $53,537.50 | 08/20/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE | No dispute reported | 06/30/2026 | 691346833 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31,342.91 | 08/14/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 639741435 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $17.40 | 08/12/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE | No dispute reported | 06/30/2026 | 691355779 |
| Principal investigator 1 | Novo Nordisk AS | $4.80 | 08/09/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | NN9535-4506 | No dispute reported | 06/30/2026 | 706668211 |
| Principal investigator 1 | Novo Nordisk AS | $4.80 | 08/09/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | NN9535-4506 | No dispute reported | 06/30/2026 | 706668213 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $186.00 | 08/07/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE | No dispute reported | 06/30/2026 | 691502007 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $196.00 | 08/07/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 639741433 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $36,785.00 | 08/06/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE | No dispute reported | 06/30/2026 | 691346823 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $186.00 | 07/31/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE | No dispute reported | 06/30/2026 | 691508557 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $41,711.46 | 07/31/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 639741431 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,280.00 | 07/23/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CHRONIC LOW BACK PAIN AND OSTEOARTHRITIS OF THE HIP OR KNEE | No dispute reported | 06/30/2026 | 639741395 |
| Principal investigator 1 | Eli Lilly and Company | $8,670.67 | 07/19/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL COMPARING EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS SEMAGLUTIDE ONCE WEEKLY AS ADD-ON THERAPY TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 654289099 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $186.00 | 07/19/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE | No dispute reported | 06/30/2026 | 691508551 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,494.69 | 07/18/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CHRONIC LOW BACK PAIN AND OSTEOARTHRITIS OF THE HIP OR KNEE | No dispute reported | 06/30/2026 | 639741393 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $11,992.47 | 07/17/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 639741429 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $25,957.59 | 07/02/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 639741427 |
| Principal investigator 1 | AbbVie, Inc. | $11,785.00 | 06/27/2019 | Non-covered Recipient Entity Artemis Institute For Clinical Research | M18-891 | No dispute reported | 06/30/2026 | 647621741 |
| Principal investigator 1 | Novo Nordisk AS | $9.98 | 06/27/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | NN9535-4506 | No dispute reported | 06/30/2026 | 706668209 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $21,578.40 | 06/26/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 639741425 |
| Principal investigator 1 | Novo Nordisk AS | $144.09 | 06/19/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | NN9535-4506 | No dispute reported | 06/30/2026 | 706668215 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $1,931.70 | 06/17/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE | No dispute reported | 06/30/2026 | 691419713 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $472.80 | 06/12/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE | No dispute reported | 06/30/2026 | 691369118 |
| Principal investigator 1 | Novo Nordisk AS | $36.00 | 06/12/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | NN9535-4506 | No dispute reported | 06/30/2026 | 706668191 |
| Principal investigator 1 | Novo Nordisk AS | $9.80 | 06/12/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | NN9535-4506 | No dispute reported | 06/30/2026 | 706668193 |
| Principal investigator 1 | Novo Nordisk AS | $6.50 | 06/12/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | NN9535-4506 | No dispute reported | 06/30/2026 | 706668195 |
| Principal investigator 1 | Novo Nordisk AS | $60.00 | 06/12/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | NN9535-4506 | No dispute reported | 06/30/2026 | 706668197 |
| Principal investigator 1 | Novo Nordisk AS | $9.00 | 06/12/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | NN9535-4506 | No dispute reported | 06/30/2026 | 706668199 |
| Principal investigator 1 | Novo Nordisk AS | $49.98 | 06/12/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | NN9535-4506 | No dispute reported | 06/30/2026 | 706668201 |
| Principal investigator 1 | Novo Nordisk AS | $5.30 | 06/12/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | NN9535-4506 | No dispute reported | 06/30/2026 | 706668203 |
| Principal investigator 1 | Novo Nordisk AS | $11.38 | 06/12/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | NN9535-4506 | No dispute reported | 06/30/2026 | 706668205 |
| Principal investigator 1 | Novo Nordisk AS | $1.14 | 06/12/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | NN9535-4506 | No dispute reported | 06/30/2026 | 706668207 |
| Principal investigator 1 | Novo Nordisk AS | $75.00 | 06/12/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | NN9535-4506 | No dispute reported | 06/30/2026 | 706668221 |
| Principal investigator 1 | Novo Nordisk AS | $117.78 | 06/12/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | NN9535-4506 | No dispute reported | 06/30/2026 | 706668223 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33,240.66 | 06/12/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 639741423 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $3,863.40 | 06/10/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE | No dispute reported | 06/30/2026 | 691410269 |
| Principal investigator 1 | Novo Nordisk AS | $63.52 | 06/10/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | NN9535-4506 | No dispute reported | 06/30/2026 | 706668165 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $10,764.00 | 06/05/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 639741419 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,150.00 | 06/05/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 639741421 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,588.62 | 05/29/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 639741391 |
| Recipient | Teva Pharmaceuticals USA, Inc. | $15.00 | 05/28/2019 | Covered Recipient Physician | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia | No dispute reported | 06/30/2026 | 685027707 |
| Recipient | Teva Pharmaceuticals USA, Inc. | $15.89 | 05/28/2019 | Covered Recipient Physician | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia | No dispute reported | 06/30/2026 | 685027715 |
| Recipient | Teva Pharmaceuticals USA, Inc. | $29.15 | 05/28/2019 | Covered Recipient Physician | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia | No dispute reported | 06/30/2026 | 685027721 |
| Recipient | Teva Pharmaceuticals USA, Inc. | $96.00 | 05/28/2019 | Covered Recipient Physician | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia | No dispute reported | 06/30/2026 | 685027729 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $15.00 | 05/24/2019 | Non-covered Recipient Individual | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia | No dispute reported | 06/30/2026 | 685027529 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $15.08 | 05/24/2019 | Non-covered Recipient Individual | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia | No dispute reported | 06/30/2026 | 685027537 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $43.77 | 05/24/2019 | Non-covered Recipient Individual | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia | No dispute reported | 06/30/2026 | 685027545 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $45.03 | 05/24/2019 | Non-covered Recipient Individual | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia | No dispute reported | 06/30/2026 | 685027551 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $213.57 | 05/24/2019 | Non-covered Recipient Individual | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia | No dispute reported | 06/30/2026 | 685027561 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $2,008.80 | 05/19/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE | No dispute reported | 06/30/2026 | 691480397 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $884.28 | 05/17/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE | No dispute reported | 06/30/2026 | 691334259 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $40,598.62 | 05/15/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 639741389 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $23,877.32 | 05/14/2019 | Non-covered Recipient Entity Artemis Clinical Research | A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis | No dispute reported | 06/30/2026 | 639763419 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $500.00 | 05/14/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE | No dispute reported | 06/30/2026 | 691346831 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $258.30 | 05/09/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CHRONIC LOW BACK PAIN AND OSTEOARTHRITIS OF THE HIP OR KNEE | No dispute reported | 06/30/2026 | 639741387 |
| Principal investigator 1 | PFIZER INC. | $82,152.85 | 05/07/2019 | Non-covered Recipient Entity Artemis Institute for Clinical Research LLC | A PHASE 3 RANDOMIZED DOUBLE BLIND PLACEBO AND ACTIVECONTROLLED MULTICENTER PARALLELGROUP STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN ADULT SUBJECTS WITH CHRONIC LOW BACK PAIN | No dispute reported | 06/30/2026 | 671655371 |
| Principal investigator 1 | Flexion Therapeutics, Inc. | $8,500.00 | 05/01/2019 | Non-covered Recipient Entity Artemis Institute for Clinical Research | A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of FX006 in Patients with Hip Osteoarthritis | No dispute reported | 06/30/2026 | 705979749 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35,959.86 | 05/01/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 639741385 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $167.30 | 04/26/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | A Phase 2a, Proof of Concept, Randomized, Double-blind, Placebo-controlled Clinical Trial, to Evaluate the Efficacy and Safety of MK-7264 in Women with Moderate to Severe Endometriosis-related Pain | No dispute reported | 06/30/2026 | 691480393 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35,594.16 | 04/24/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 639741417 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $7,500.00 | 04/23/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE | No dispute reported | 06/30/2026 | 691312429 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,221.33 | 04/10/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 639741415 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $50,077.53 | 03/27/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 639741413 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $2,361.25 | 03/21/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | A Phase 2a, Proof of Concept, Randomized, Double-blind, Placebo-controlled Clinical Trial, to Evaluate the Efficacy and Safety of MK-7264 in Women with Moderate to Severe Endometriosis-related Pain | No dispute reported | 06/30/2026 | 691312275 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $3,999.92 | 03/19/2019 | Non-covered Recipient Entity Artemis Institute For Clinical Research - San Diego | A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to | No dispute reported | 06/30/2026 | 639763417 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $26,954.98 | 03/13/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 639741411 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $54,672.35 | 03/04/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 639741409 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,796.00 | 02/20/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 639741407 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $13,624.00 | 02/13/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 639741403 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9,495.54 | 02/13/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 639741405 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $1,660.00 | 02/07/2019 | Non-covered Recipient Entity Artemis Institute For Clinical Research | Bay1002670 Fibroids Efficacy US / EU | No dispute reported | 06/30/2026 | 629168583 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $1,660.00 | 02/07/2019 | Non-covered Recipient Entity Artemis Institute For Clinical Research | Bay1002670 Fibroids Efficacy US / EU | No dispute reported | 06/30/2026 | 629168845 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $45,773.94 | 02/06/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 639741401 |
| Principal investigator 1 | Eli Lilly and Company | $155,744.00 | 01/29/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF INVESTIGATIONAL DULAGLUTIDE DOSES WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | No dispute reported | 06/30/2026 | 654288057 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $83,008.00 | 01/24/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When administered Concomitantly with Influenza Vaccine in Healthy Adults 50 Years of Age or Older PNEU -FLU | No dispute reported | 06/30/2026 | 691306131 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $3,010.60 | 01/22/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | A Phase 2a, Proof of Concept, Randomized, Double-blind, Placebo-controlled Clinical Trial, to Evaluate the Efficacy and Safety of MK-7264 in Women with Moderate to Severe Endometriosis-related Pain | No dispute reported | 06/30/2026 | 691306121 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $55.70 | 01/22/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | A Phase 2a, Proof of Concept, Randomized, Double-blind, Placebo-controlled Clinical Trial, to Evaluate the Efficacy and Safety of MK-7264 in Women with Moderate to Severe Endometriosis-related Pain | No dispute reported | 06/30/2026 | 691480399 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,957.80 | 01/16/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 639741399 |
| Recipient | Eli Lilly and Company | $6,233.00 | 01/08/2019 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF INVESTIGATIONAL DULAGLUTIDE DOSES WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | No dispute reported | 06/30/2026 | 654283525 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $55,934.50 | 01/08/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When administered Concomitantly with Influenza Vaccine in Healthy Adults 50 Years of Age or Older PNEU -FLU | No dispute reported | 06/30/2026 | 691306127 |
| Principal investigator 1 | Eli Lilly and Company | $17,009.05 | 01/03/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF INVESTIGATIONAL DULAGLUTIDE DOSES WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | No dispute reported | 06/30/2026 | 654288185 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $214.50 | 01/03/2019 | Non-covered Recipient Entity ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP | No dispute reported | 06/30/2026 | 639741397 |